|
|
| Year : 1998 | Volume
: 14
| Issue : 1 | Page : 34-36 |
|
|
Terazosin in management of benign prostatic hyperplasia
NK Mohanty, AK Jha, M Khetan, RP Arora
Department of Urology, Safdarjang Hospital, New Delhi
Correspondence Address:
N K Mohanty
Department of Urology, Safdarjang Hospital, New Delhi
 Source of Support: None, Conflict of Interest: None  | Check |
|
|
|
The rationale for alpha/blockade in benign prostatic hyperplasia is based upon the fact that these alpha under one adrenoreceptors are abundantly present over prostate capsule, bladder neck, prostatic urethra and smooth muscle of prostate, and blockade of these receptors by alpha; antagonist would result in relaxation of the bladder outlet obstruction. The present single label study was to determine the efficacy and safety of Terazosin in management of Benign Prostatic Hyperplasia (BPH) in one hundred patients using 5 nig of Teralpha daily for three months and followed up for twelve months with uroflowrate, ultrasonography and symptom score. Our result shows that Terazosin produced a significant improvement in subjective symptoms with increase inpeak and mean flow rate and decrease in postmicturition urine volume with very little adverse effects. This study therefore revealed the short term efficacy and safety of Terazosin therapy in BPH and its long term efficacy and safety is to be evaluated. |
|
|
|
| [PDF Not available]* |
|
 |
|
